Pila Pharma Q3 2022: Funding In Focus

Research Note



Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022. We comment on yesterday's rights issue, the content in the report, and lower our Base case.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.